Benzinga | Nov 23, 2020 09:12AM EST

AIM ImmunoTech Says Was Informed That First Patient Has Been Enrolled And Commenced Treatment In Phase 1/2a Study At Roswell Park Comprehensive Cancer Center Evaluating Ampligen With alpha-2b For Cancer And Mild-To-Moderate COVID-19

AIM ImmunoTech Inc. was informed after closing of the market on November 20, 2020 that the first patient has been enrolled and commenced treatment in a Phase 1/2a study at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y. evaluating AIM's Ampligen in combination with interferon alpha-2b, as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19, the disease caused by SARS-CoV-2.



The Roswell Park clinical trial plans to enroll up to 44 patients and full trial details are available at https://www.clinicaltrials.gov/ct2/show/NCT04379518.